We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

8 hedge funds and large institutions have $2.38M invested in CERo Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more capital invested

Capital invested by funds: $528K → $2.38M (+$1.85M)

46.62% more ownership

Funds ownership: 1.19% → 47.82% (+47%)

38% less funds holding

Funds holding: 13 → 8 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
8
Holders Change
-5
Holders Change %
-38.46%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
1
Increased
7
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Parallel Advisors
California
+$2.6M
2
AVM
Arch Venture Management
Illinois
+$265K
3
FIA
FNY Investment Advisers
New York
+$12.9K
4
UBS Group
UBS Group
Switzerland
+$6.11K
5
TRCT
Tower Research Capital (TRC)
New York
+$5.39K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$228K
2
APP
Avantax Planning Partners
Iowa
-$54.3K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$12.3K
4
Citadel Advisors
Citadel Advisors
Florida
-$11.8K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$9.74K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Parallel Advisors
California
$2.12M +$2.6M +209,000 +1,900%
AVM
2
Arch Venture Management
Illinois
$216K +$265K +21,284 +1,926%
UBS Group
3
UBS Group
Switzerland
$25.3K +$6.11K +491 +23%
FIA
4
FNY Investment Advisers
New York
$10K +$12.9K +1,037 +7,977%
TRCT
5
Tower Research Capital (TRC)
New York
$6.59K +$5.39K +433 +173%
SS
6
SBI Securities
Japan
$173 +$149 +12 +200%
Jones Financial Companies
7
Jones Financial Companies
Missouri
$29 +$37 +3 New
Bank of America
8
Bank of America
North Carolina
$19 +$12 +1 +100%
AC
9
Armistice Capital
New York
– -$228K -15,600 Closed
APP
10
Avantax Planning Partners
Iowa
– -$54.3K -3,716 Closed
Geode Capital Management
11
Geode Capital Management
Massachusetts
– -$12.3K -846 Closed
Citadel Advisors
12
Citadel Advisors
Florida
– -$11.8K -811 Closed
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
– -$9.74K -667 Closed
Barclays
14
Barclays
United Kingdom
– -$74 -5 Closed
JP Morgan Chase
15
JP Morgan Chase
New York
– -$1 – –
Osaic Holdings
16
Osaic Holdings
Arizona
– -$2 – –

CERO Hedge Fund Activity: Q2 2025 in Review

8 of the 7,598 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q2 2025, worth a combined $2.38M — up 350% from $528K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of CERO and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 7 added.

The largest buyer was Parallel Advisors, adding an estimated $2.6M. The largest seller was Armistice Capital, exiting entirely with an estimated $228K sold.

  • 8 institutional investors held CERo Therapeutics (CERO) as of Q2 2025, down from 13 in Q1 2025.
  • Funds reported $2.38M of CERo Therapeutics stock for Q2 2025, up 350% quarter-over-quarter.
  • 1 fund opened new CERo Therapeutics positions in Q2 2025 and 6 closed out, a net change of -5 holders.
  • The largest CERo Therapeutics buyer in Q2 2025 was Parallel Advisors, an estimated $2.6M added.
  • The largest CERo Therapeutics seller in Q2 2025 was Armistice Capital, an estimated $228K sold.

Based on aggregated 13F filings for Q2 2025.